This company has been acquired
Dividendos de Paratek Pharmaceuticals
Dividendo controles de criterios 0/6
Paratek Pharmaceuticals does not have a record of paying a dividend.
Información clave
n/a
Rentabilidad por dividendo
n/a
Ratio de pago
Rentabilidad media de la industria | 2.3% |
Próxima fecha de pago de dividendos | n/a |
Fecha ex dividendo | n/a |
Dividendo por acción | n/a |
Beneficios por acción | -US$1.09 |
Rentabilidad por dividendo prevista a 3 años | n/a |
Últimas actualizaciones de dividendos
No hay actualizaciones
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: Insufficient data to determine if PRTK's dividends per share have been stable in the past.
Dividendo creciente: Insufficient data to determine if PRTK's dividend payments have been increasing.
Rentabilidad por dividendo vs. Mercado
Rentabilidad por dividendo de Paratek Pharmaceuticals vs. Mercado |
---|
Segmento | Rentabilidad por dividendo |
---|---|
Empresa (PRTK) | n/a |
Suelo de mercado 25% (US) | 1.5% |
Techo de mercado 25% (US) | 4.8% |
Media de la industria (Pharmaceuticals) | 2.3% |
Previsión de analistas en 3 años (PRTK) | n/a |
Dividendo destacado: Unable to evaluate PRTK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Alto dividendo: Unable to evaluate PRTK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Pago de beneficios a los accionistas
Cobertura de los beneficios: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Unable to calculate sustainability of dividends as PRTK has not reported any payouts.